Navigation Links
Basic Scientist Mark Roth Wins MacArthur Fellowship
Date:9/25/2007

Cell biologist receives $500,000 'genius award' with 'no strings attached'

SEATTLE, Sept. 25 /PRNewswire/ -- Mark Roth, Ph.D., a cell biologist at Fred Hutchinson Cancer Research Center, is among 24 recipients of this year's MacArthur Fellowships, a "genius" award given annually by the John D. and Catherine T. MacArthur Foundation. Roth will receive $500,000 over five years of "no-strings-attached" support.

Roth, a member of the Hutchinson Center's Basic Sciences Division, is perhaps best known for his research in reversible metabolic hibernation, a technique that one day may be used to help "buy time" for critically ill trauma patients on organ-transplant lists and in operating rooms, emergency rooms and battlefields.

"I'm just incredibly humbled and happy to be recognized by such a wonderful organization," said Roth, who has pursued a variety of research avenues, including studies on gene regulation, chromosome structure and function, autoimmune disease and, most recently, induced metabolic hibernation.

"The creative work I've been able to do has depended upon my interaction with people from vastly different scientific backgrounds -- people whose scientific orbits wouldn't normally intersect with mine. I'm hoping this fellowship will increase the possibility for more such creative collaborations," he said.

The MacArthur Fellowship Program was established in 1981 and includes 756 Fellows. In addition to Roth, those honored this year include a forensic anthropologist, a spider-silk biologist, a short-story writer, a nanotechnologist, a choreographer and a master vocalist, among others.

"As a group, this new class of Fellows takes one's breath away," said Daniel J. Socolow, director of the MacArthur Fellows Program, in a written statement. "As individuals, each is an original. To the person, they confirm that the creative individual is alive and well, at the cutting edge, and at work singularly and powerfully to make our world a better place. They are people who will change and influence our times."

Roth's work has led to major advances in basic biology, some of which have tremendous potential for human health. In particular, his research on induced metabolic hibernation, in which he has reversibly reduced the core temperature of mice to 10 degrees Celsius without loss of life or neurological problems, could one day lead to major breakthroughs for a host of human ills caused by tissue damage from a lack of oxygen.

"Mark is an exceptionally creative and innovative scientist who has pursued successfully more original avenues of research than anyone I know," said Roth's colleague Mark Groudine, M.D., Ph.D., a member of the Basic Sciences Division and deputy director of the Hutchinson Center. "In all cases, his rare ability to identify a seemingly intractable problem and tackle it with unswerving focus -- even when it required him to learn a completely new field, establish new collaborations, challenge conventional wisdom or develop new technology -- has led to major advances in basic biology, some of which have tremendous potential for human health. In particular, his new research on metabolic flexibility could lead to major breakthroughs in the treatment of stroke, trauma and cancer."

To help move this work forward into the clinical setting, Roth in 2005 founded a Seattle biotechnology company called Ikaria Inc., which earlier this year merged with INO Therapeutics to become Ikaria Holdings, a leader in the development of therapeutic gases for use in critical-care medicine. The company, based in Clinton, N.J., also operates a research and development facility in Seattle.

Earlier this year Roth received the 2007 Award for Significant Technical Achievement by the Defense Advanced Research Projects Agency, or DARPA, a major supporter of his work, for developing technology that "could dramatically improve the survival rate of wounded fighters and provide revolutionary improvements in the prevention and control of other medical complications on the battlefield."

Roth, who joined the Basic Sciences Division at the Hutchinson Center in 1989, is also an affiliate associate professor of biochemistry at the University of Washington. His numerous scientific articles have appeared in such publications as Science, Proceedings of the National Academy of Sciences and the Journal of Cell Biology.

He received a bachelor of science in 1979 from the University of Oregon and a doctorate in 1984 from the University of Colorado at Boulder.

For more information about the MacArthur Fellowship Program, visit http://www.macfound.org.

At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit fhcrc.org.

CONTACT

Kristen Woodward

(206) 667-5095

kwoodwar@fhcrc.org


'/>"/>
SOURCE Fred Hutchinson Cancer Research Center
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Basic Plasmid DNA Isolation Protocol
2. Basic Plasmid DNA Isolation Protocol
3. Array Analysis: The Basics
4. Northern Analysis: The Basics
5. Nuclease Protection Assays: The Basics
6. TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds
7. FERMENTATION BASICS
8. UW computer scientists fighting computer virus "Cold War"
9. UW scientist, former WiCell director found stem cell company
10. Scientists find way to make human collagen in lab
11. Wisconsin scientists to be recognized for innovative biofuel technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... A study ... completed in an ambulatory surgery center (ASC) with satisfactory clinical and patient-reported outcomes, ... TDR studies. , Jake Lubinski, president of AxioMed, commented on the recent ...
(Date:2/24/2017)... , Feb. 24, 2017 Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... deadline to participate in its previously announced rights ... of shares of common stock and Series C ... of listed warrants. As previously ...
(Date:2/24/2017)... N.J. , Feb. 24, 2017  Driven ... and biotechnology are now the fastest growing categories, ... Specialty Actives in Personal Care: Multi-regional Market ... research and management consulting firm Kline. ... bioprocesses that make them more effective for skin ...
(Date:2/24/2017)... Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), ... announced its financial results for the fourth quarter and fiscal ... Highlights Total sales in the fourth ... increased by 13.6% in USD terms to $77.6 million from ... Gross profit increased by 13.3% to $46.8 million from ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017  EyeLock LLC, a market leader ... white paper " What You Should Know About Biometrics ... ensuring user authenticity is a growing concern. In traditional ... users. However, traditional authentication schemes such as username/password suffer ... Biometric authentication offers an elegant solution to the problem ...
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
(Date:1/26/2017)...  Acuity Market Intelligence today released the 2017 ...  Acuity characterizes 2017 as a "breakout" year for ... a new understanding of the potential benefits these ... identity are often perceived as threats to privacy ... of Acuity Market intelligence. "However, taken together these ...
Breaking Biology News(10 mins):